Literature DB >> 10694212

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.

A Tahara1, J Tsukada, Y Tomura, K i Wada, T Kusayama, N Ishii, T Yatsu, W Uchida, A Tanaka.   

Abstract

[(3)H]-oxytocin was used to characterize the oxytocin receptor found in human uterine smooth muscle cells (USMC). Specific binding of [(3)H]-oxytocin to USMC plasma membranes was dependent upon time, temperature and membrane protein concentration. Scatchard plot analysis of equilibrium binding data revealed the existence of a single class of high-affinity binding sites with an apparent equilibrium dissociation constant (K(d)) of 0.76 nM and a maximum receptor density (B(max)) of 153 fmol mg(-1) protein. The Hill coefficient (n(H)) did not differ significantly from unity, suggesting binding to homogenous, non-interacting receptor populations. Competitive inhibition of [(3)H]-oxytocin binding showed that oxytocin and vasopressin (AVP) receptor agonists and antagonists displaced [(3)H]-oxytocin in a concentration-dependent manner. The order of potencies for peptide agonists and antagonists was: oxytocin>[Asu(1,6)]-oxytocin>AVP= atosiban>d(CH(2))(5)Tyr(Me)AVP>[Thr(4),Gly(7)]-oxytocin>dDAVP, and for nonpeptide antagonists was: L-371257>YM087>SR 49059>OPC-21268>SR 121463A>OPC-31260. Oxytocin significantly induced concentration-dependent increase in intracellular Ca(2+) concentration ([Ca(2+)](i)) and hyperplasia in USMC. The oxytocin receptor antagonists, atosiban and L-371257, potently and concentration-dependently inhibited oxytocin-induced [Ca(2+)](i) increase and hyperplasia. In contrast, the V(1A) receptor selective antagonist, SR 49059, and the V(2) receptor selective antagonist, SR 121463A, did not potently inhibit oxytocin-induced [Ca(2+)](i) increase and hyperplasia. The potency order of antagonists in inhibiting oxytocin-induced [Ca(2+)](i) increase and hyperplasia was similar to that observed in radioligand binding assays. In conclusion, these data provide evidence that the high-affinity [(3)H]-oxytocin binding site found in human USMC is a functional oxytocin receptor coupled to [Ca(2+)](i) increase and cell growth. Thus human USMC may prove to be a valuable tool in further investigation of the physiologic and pathophysiologic roles of oxytocin in the uterus. British Journal of Pharmacology (2000) 129, 131 - 139

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694212      PMCID: PMC1621120          DOI: 10.1038/sj.bjp.0702996

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Oxytocin receptors: triggers for parturition and lactation?

Authors:  M S Soloff; M Alexandrova; M J Fernstrom
Journal:  Science       Date:  1979-06-22       Impact factor: 47.728

2.  Oxytocin gene expression in rat uterus.

Authors:  D L Lefebvre; A Giaid; H Bennett; R Larivière; H H Zingg
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

3.  Oxytocin receptors in rat oviduct.

Authors:  M S Soloff
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

4.  Characterization of oxytocin receptors on isolated rat fat cells.

Authors:  D Bonne; P Cohen
Journal:  Eur J Biochem       Date:  1975-08-01

5.  Characterization of oxytocin receptors in the uterus and mammary gland.

Authors:  M S Soloff; B T Schroeder; J Chakraborty; A F Pearlmutter
Journal:  Fed Proc       Date:  1977-05

6.  Crystalline deamino-dicarba-oxytocin. Preparation and some pharmacological properties.

Authors:  T Yamanaka; S Hase; S Sakakibara; I L Schwartz; B M Dubois; R Walter
Journal:  Mol Pharmacol       Date:  1970-09       Impact factor: 4.436

Review 7.  Role of prostaglandins, prostacyclin, and thromboxanes in the physiologic control of the uterus and in parturition.

Authors:  M J Novy; G C Liggins
Journal:  Semin Perinatol       Date:  1980-01       Impact factor: 3.300

8.  Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity.

Authors:  J Lowbridge; M Manning; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1977-01       Impact factor: 7.446

9.  Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor.

Authors:  A R Fuchs; F Fuchs; P Husslein; M S Soloff; M J Fernström
Journal:  Science       Date:  1982-03-12       Impact factor: 47.728

10.  [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

Authors:  M Kruszynski; B Lammek; M Manning; J Seto; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

View more
  11 in total

1.  Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Authors:  J Tsukada; A Tahara; Y Tomura; T Kusayama; N Ishii; T Yatsu; W Uchida; N Taniguchi; A Tanaka
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Skeletal Muscle-Specific Activation of Gq Signaling Maintains Glucose Homeostasis.

Authors:  Derek B J Bone; Jaroslawna Meister; Jonas R Knudsen; Diptadip Dattaroy; Amanda Cohen; Regina Lee; Huiyan Lu; Daniel Metzger; Thomas E Jensen; Jürgen Wess
Journal:  Diabetes       Date:  2019-04-01       Impact factor: 9.461

3.  Analysis of decay kinetics of the cytosolic calcium transient induced by oxytocin in rat myometrium smooth muscle cells.

Authors:  S O Karakhim; S G Shlykov; L G Babich; D V Sinko
Journal:  J Muscle Res Cell Motil       Date:  2021-02-15       Impact factor: 2.698

4.  β-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration.

Authors:  Chad A Grotegut; Liping Feng; Lan Mao; R Phillips Heine; Amy P Murtha; Howard A Rockman
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-07       Impact factor: 4.310

5.  Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway.

Authors:  Miao Zhong; Maryam L Boseman; Ana C Millena; Shafiq A Khan
Journal:  Mol Cancer Res       Date:  2010-07-27       Impact factor: 5.852

6.  Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling.

Authors:  Elena A Zalyapin; Richard Bouley; Udo Hasler; Jean-Pierre Vilardaga; Herbert Y Lin; Dennis Brown; Dennis A Ausiello
Journal:  Kidney Int       Date:  2008-08-27       Impact factor: 10.612

Review 7.  Oxytocin receptor signaling in myoepithelial and cancer cells.

Authors:  Alessandra Reversi; Paola Cassoni; Bice Chini
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-07       Impact factor: 2.698

8.  Sequence variants in oxytocin pathway genes and preterm birth: a candidate gene association study.

Authors:  Jinsil Kim; Kara J Stirling; Margaret E Cooper; Mario Ascoli; Allison M Momany; Erin L McDonald; Kelli K Ryckman; Lindsey Rhea; Kendra L Schaa; Viviana Cosentino; Enrique Gadow; Cesar Saleme; Min Shi; Mikko Hallman; Jevon Plunkett; Kari A Teramo; Louis J Muglia; Bjarke Feenstra; Frank Geller; Heather A Boyd; Mads Melbye; Mary L Marazita; John M Dagle; Jeffrey C Murray
Journal:  BMC Med Genet       Date:  2013-07-26       Impact factor: 2.103

9.  Functional in vitro tension measurements of fascial tissue - a novel modified superfusion approach.

Authors:  R Schleip; W Klingler; S Wearing; I Naylor; M Zuegel; K Hoppe
Journal:  J Musculoskelet Neuronal Interact       Date:  2016-09-07       Impact factor: 2.041

10.  In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications.

Authors:  Susan Hua; Benjamin Vaughan
Journal:  Int J Nanomedicine       Date:  2019-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.